LangopeptЛангопепт
An investigational peptide preparation derived from bronchial tissue. Russian trial registrations describe dose escalation in healthy volunteers and a Phase II study in chronic obstructive pulmonary disease. The registrations give study plans.
What the studies found
Lab research · 2025
EDG at 1 ng/mL in rat lung, bronchial and arterial explants
Related laboratory finding · isolated EDG
- Lung explant area index
- +21 ± 3% versus controlDay 3p<0.05, Table 1
- Bronchial explant area index
- +3 ± 1% versus controlDay 3No significant difference reported, Table 2
- Bronchial artery explant area index
- +3 ± 1% versus controlDay 3No significant difference reported, Table 3
An experiment with isolated EDG at 1 ng/mL increased rat lung-explant area index by 21 ± 3%. Changes in bronchial and bronchial artery tissue were small and statistically inconclusive. The result applies to isolated EDG.
Study notes · methods, sources and limitations
Participants or model Three-month-old Wistar rats provided 230 lung, 200 bronchial and 210 bronchial artery explants across all experiments. Each dish contained 18–20 explants. The report does not give EDG-specific counts or the number of donor rats.
Design Organotypic tissue culture with phase-contrast microscopy. Investigators calculated total explant area relative to the central zone and set the control index to 100%.
- Explants across all experiments
- 230 lung, 200 bronchial and 210 bronchial artery explants. Each dish contained 18–20 explants.The authors give no EDG-specific counts or total number of donor rats.
Important limitations
- The area index measures laboratory explant growth. The authors do not give the EDG-specific group sizes or number of source animals. The exposure concerns EDG alone, so the findings apply to that peptide in this assay.
Integrative Physiology. 2025;6(3):329–337. · Publication record
Laboratory analysis · 2020
Identification of short peptides in the composition of polypeptide complexes isolated from animal organs
Findings for this preparation
- EDG and AEDL in the bronchial mucosa complex
- EDG 0.028% and AEDL 0.060% of the analyzed extract
UHPLC–MS detected 0.028% EDG and 0.060% AEDL in the bronchial mucosa extract. The analysis does not identify the clinical trial batch.
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology · Pavlov Institute of Physiology, Russian Academy of Sciences · Institute of Toxicology, Federal Medical-Biological Agency
Study notes · methods, sources and limitations
Participants or model Animal-organ polypeptide complexes analyzed by UHPLC–MS
Design UHPLC–tandem mass spectrometry of six lyophilized animal-tissue complexes, using reference standards for seven target sequences.
Important limitations
- Molecular detection does not prove identical pharmacology or clinical equivalence. The paper’s discussion of clinical work is not an independent clinical trial.
- These measurements describe the analyzed preparations. The paper does not characterize all constituents or identify the clinical trial batch.
Uspekhi Sovremennoi Biologii 140(2):140–148 · Publication record
About Langopept
Names in this research collection
Langopept COPD · LNG-11-2022 · LNG-04-2019
Identity / background source ↗
Research background
An investigational peptide mixture prepared from calf bronchial mucosa and formulated for intramuscular injection. Human trial registrations, a preclinical conference report, and laboratory findings on individual peptides are linked below.
More study findings
Planned study · 2023
Langopept Phase II placebo-controlled COPD trial registration
PeptidPRO’s double-blind COPD trial lists 200 planned participants. Clinomir marks the study completed. Actual enrollment, doses administered and results remain unavailable.
Study notes · methods, sources and limitations
Participants or model 200 planned participants with moderate-to-severe chronic obstructive pulmonary disease (COPD). Actual enrollment and arm sizes are unavailable.
Design Multicenter, double-blind, randomized, parallel-group placebo-controlled design. ClinLine lists investigators T. I. Ishina, V. V. Popov and N. D. Krasnopeeva.
- Planned enrollment
- 200 participants
Important limitations
- The registry target was 200. Clinomir gives an administrative completion status without participant flow, study endpoint data, or adverse-event tables.
Russian clinical-trial registry record, authorization 262, 5 May 2023. Protocol LNG-11-2022. · Trial registry reproduction
Planned study · 2019
Langopept Phase I dose-escalation registration
MedInvest’s Phase I record lists 42 planned healthy volunteers. Clinomir marks the study completed. Actual enrollment, dose steps and safety results remain unavailable.
Study notes · methods, sources and limitations
Participants or model 42 healthy adults planned at Kazan Federal University. The entry does not report actual enrollment or cohort sizes.
Design Randomized, double-blind, placebo-controlled, ascending-dose study at Kazan Federal University. The registry identifies G. M. Kamalov as investigator.
- Planned enrollment
- 42 healthy volunteers
Important limitations
- The registry lists a study design and formulation strength. It supplies no treatment outcomes or adverse-event counts.
Russian clinical-trial registry record, authorization 504, 6 September 2019. Protocol LNG-04-2019. · Trial registry reproduction
Research record · 2017
Langopept extract in an early preclinical conference report
- Reported experimental findings for the extract
- The authors describe changes in bronchial mucosal metabolism and repair of alveolar and bronchial epithelium.
The developers described effects on bronchial mucosal metabolism and on the repair of alveolar and bronchial epithelium in experimental models. The abstract gives no numerical outcomes.
Study notes · methods, sources and limitations
Participants or model The abstract refers to experimental models without giving a species, model protocol, or number per group for Langopept.
Design Conference summary from the St. Petersburg Institute of Bioregulation and Gerontology, describing several preparations in development.
Important limitations
- The conference abstract does not identify the Langopept models, group sizes, comparators, endpoints, or effect sizes. It predates both trial registrations.
Uspekhi Gerontologii. 2017;30(6 Suppl):67. Innovative Russian Technologies in Gerontology and Geriatrics, St. Petersburg, 14–16 December 2017. · Conference abstract · preclinical program summary
- Compound class
- Tissue-derived peptide preparation
- Research collection
- Peptide bioregulation · editorial grouping
- Institutions in linked studies
- St. Petersburg Institute of Bioregulation and Gerontology · Pavlov Institute of Physiology, Russian Academy of Sciences · Institute of Toxicology, Federal Medical-Biological Agency
- Source review
- Review dates and the material assessed are listed with each publication below.
Understanding the evidence
Human research
Phase I: 42 healthy volunteers planned. Phase II: 200 COPD patients planned.
Study methods
Double-blind placebo-controlled designs. Actual enrollment and dosing schedules are unavailable.
Independent replication
Comparative findings are unavailable in the linked records.
Source access
Russian registry entries for protocols LNG-04-2019 and LNG-11-2022.
Safety evidence
Phase I was designed to assess tolerability. Adverse-event results are unavailable.
Open a topic for the evidence assessment.
Findings by study
Planned study · 2023
Langopept Phase II placebo-controlled COPD trial registration
PeptidPRO’s double-blind COPD trial lists 200 planned participants. Clinomir marks the study completed. Actual enrollment, doses administered and results remain unavailable.
Study notes and original source
Langopept Phase II placebo-controlled COPD trial registration
· Trial registry reproduction
PeptidPRO · Russian clinical-trial registry record, authorization 262, 5 May 2023. Protocol LNG-11-2022.
PeptidPRO’s double-blind COPD trial lists 200 planned participants. Clinomir marks the study completed. Actual enrollment, doses administered and results remain unavailable.
Results and tables
Reported findings and study design
The patent gives no measured outcomes
Multicenter, double-blind, randomized, parallel-group placebo-controlled design. ClinLine lists investigators T. I. Ishina, V. V. Popov and N. D. Krasnopeeva.
Dose, route and schedule
The registry lists a 5 mg lyophilized formulation for intramuscular injection and a placebo control. It does not give the per-visit dose, frequency or treatment duration.
Protocol source ↗ · ClinLine trial entry and Clinomir sponsor listing for PeptidPRO.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Planned enrollment | 200 participants |
Source for these results ↗ · Reviewed 2026-11-15
- Population / setting
- 200 planned participants with moderate-to-severe chronic obstructive pulmonary disease (COPD). Actual enrollment and arm sizes are unavailable.
- Source reviewed
- ClinLine trial entry and Clinomir sponsor listing for PeptidPRO.
Study limitations
- The registry target was 200. Clinomir gives an administrative completion status without participant flow, study endpoint data, or adverse-event tables.
Reviewed 2026-11-15.
Planned study · 2019
Langopept Phase I dose-escalation registration
MedInvest’s Phase I record lists 42 planned healthy volunteers. Clinomir marks the study completed. Actual enrollment, dose steps and safety results remain unavailable.
Study notes and original source
Langopept Phase I dose-escalation registration
· Trial registry reproduction
MedInvest · Russian clinical-trial registry record, authorization 504, 6 September 2019. Protocol LNG-04-2019.
MedInvest’s Phase I record lists 42 planned healthy volunteers. Clinomir marks the study completed. Actual enrollment, dose steps and safety results remain unavailable.
Results and tables
Reported findings and study design
The patent gives no measured outcomes
Randomized, double-blind, placebo-controlled, ascending-dose study at Kazan Federal University. The registry identifies G. M. Kamalov as investigator.
Dose, route and schedule
Single and then repeated escalating intramuscular doses versus placebo. The registry lists a 5 mg vial. Dose levels, intervals and duration are unavailable.
Protocol source ↗ · ClinLine trial entry, MedInvest sponsor listing and Kazan Federal University investigator record.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Planned enrollment | 42 healthy volunteers |
Source for these results ↗ · Reviewed 2026-11-15
- Population / setting
- 42 healthy adults planned at Kazan Federal University. The entry does not report actual enrollment or cohort sizes.
- Source reviewed
- ClinLine trial entry, MedInvest sponsor listing and Kazan Federal University investigator record.
Study limitations
- The registry lists a study design and formulation strength. It supplies no treatment outcomes or adverse-event counts.
Reviewed 2026-11-15.
Research record · 2017
Langopept extract in an early preclinical conference report
The developers described effects on bronchial mucosal metabolism and on the repair of alveolar and bronchial epithelium in experimental models. The abstract gives no numerical outcomes.
Study notes and original source
Langopept extract in an early preclinical conference report
Polypeptide complex prepared from calf bronchial mucosa, named Langopept in the abstract. · Conference abstract · preclinical program summary
G. A. Ryzhak, V. N. Rutkovskaya, A. P. Ryzhak · Uspekhi Gerontologii. 2017;30(6 Suppl):67. Innovative Russian Technologies in Gerontology and Geriatrics, St. Petersburg, 14–16 December 2017.
The developers described effects on bronchial mucosal metabolism and on the repair of alveolar and bronchial epithelium in experimental models. The abstract gives no numerical outcomes.
Results and tables
Reported findings and study design
Findings described in words
Conference summary from the St. Petersburg Institute of Bioregulation and Gerontology, describing several preparations in development.
Population or model The abstract refers to experimental models without giving a species, model protocol, or number per group for Langopept.
Protocol information
The abstract gives no dose, route, or schedule for Langopept.
Protocol source ↗ · Russian abstract on printed page 67 of the journal supplement, recovered via the indexed copy. The meeting program confirms the presentation.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Reported experimental findings for the extract | The authors describe changes in bronchial mucosal metabolism and repair of alveolar and bronchial epithelium. |
Source for these results ↗ · Reviewed 2026-11-15
- Population / setting
- The abstract refers to experimental models without giving a species, model protocol, or number per group for Langopept.
- Source reviewed
- Russian abstract on printed page 67 of the journal supplement, recovered via the indexed copy. The meeting program confirms the presentation.
Study limitations
- The conference abstract does not identify the Langopept models, group sizes, comparators, endpoints, or effect sizes. It predates both trial registrations.
Reviewed 2026-11-15.
Lab research · 2025
EDG at 1 ng/mL in rat lung, bronchial and arterial explants
An experiment with isolated EDG at 1 ng/mL increased rat lung-explant area index by 21 ± 3%. Changes in bronchial and bronchial artery tissue were small and statistically inconclusive. The result applies to isolated EDG.
Study notes and original source
EDG at 1 ng/mL in rat lung, bronchial and arterial explants
Defined Glu–Asp–Gly (EDG, Chonluten), a sequence detected in the bronchial extract. The experiment used the individual peptide.
N. I. Chalisova, P. N. Ivanova, E. S. Egozova, E. A. Nikitina · Integrative Physiology. 2025;6(3):329–337.
At 1 ng/mL, EDG increased the lung explant area index by 21 ± 3% versus control. The index rose by 3 ± 1% in bronchial and bronchial artery cultures, with neither change statistically significant.
Results and tables
Reported findings and study design
Organotypic tissue culture with phase-contrast microscopy. Investigators calculated total explant area relative to the central zone and set the control index to 100%.
Dose, route and schedule
EDG at 1 ng/mL in 3 mL of culture medium for three days at 37 °C. Control dishes received the same medium without added peptide.
Protocol source ↗ · Original article, culture methods, explant counts and Tables 1–3. Results here concern the EDG arm.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Lung explant area index | +21 ± 3% versus control | Day 3 · p<0.05, Table 1 |
| Bronchial explant area index | +3 ± 1% versus control | Day 3 · No significant difference reported, Table 2 |
| Bronchial artery explant area index | +3 ± 1% versus control | Day 3 · No significant difference reported, Table 3 |
| Explants across all experiments | 230 lung, 200 bronchial and 210 bronchial artery explants. Each dish contained 18–20 explants. | The authors give no EDG-specific counts or total number of donor rats. |
Source for these results ↗ · Reviewed 2026-11-15
- Population / setting
- Three-month-old Wistar rats provided 230 lung, 200 bronchial and 210 bronchial artery explants across all experiments. Each dish contained 18–20 explants. The report does not give EDG-specific counts or the number of donor rats.
- Source reviewed
- Original article, culture methods, explant counts and Tables 1–3. Results here concern the EDG arm.
Study limitations
- The area index measures laboratory explant growth. The authors do not give the EDG-specific group sizes or number of source animals. The exposure concerns EDG alone, so the findings apply to that peptide in this assay.
Reviewed 2026-11-15.
Laboratory analysis · 2020
Identification of short peptides in the composition of polypeptide complexes isolated from animal organs
UHPLC–MS detected 0.028% EDG and 0.060% AEDL in the bronchial mucosa extract. The analysis does not identify the clinical trial batch.
Study notes and original source
Identification of short peptides in the composition of polypeptide complexes isolated from animal organs
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology · Pavlov Institute of Physiology, Russian Academy of Sciences · Institute of Toxicology, Federal Medical-Biological Agency
I. K. Zhurkovich, N. G. Kovrov, G. A. Ryzhak, E. S. Mironova, V. Kh. Khavinson · Uspekhi Sovremennoi Biologii 140(2):140–148
Reports KED in vessel complex, AED in cartilage, EDG and AEDL in bronchial mucosa, EDR in brain and KEDW in pancreas. This strengthens sequence-level links in the research program.
Results and tables
Reported findings and study design
UHPLC–tandem mass spectrometry of six lyophilized animal-tissue complexes, using reference standards for seven target sequences.
Population or model Animal-organ polypeptide complexes analyzed by UHPLC–MS
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| EDG and AEDL in the bronchial mucosa complex | EDG 0.028% and AEDL 0.060% of the analyzed extract |
Identified short peptides by extract
| Extract | Sequence | Reported proportion |
|---|---|---|
| Bronchial mucosa | EDG | 0.028% |
| Bronchial mucosa | AEDL | 0.060% |
| Vessels | KED | 0.020% |
| Cartilage | AED | 0.020% |
| Brain | EDR | 0.024% |
| Pancreas | KEDW | 0.035% |
These measurements describe the analyzed preparations. The paper does not characterize all constituents or identify the clinical trial batch.
Source for these results ↗ · Reviewed 2026-11-15
- Population / setting
- Animal-organ polypeptide complexes analyzed by UHPLC–MS
- Source reviewed
- Original analytical paper, test method, Table 3 and chromatograms in Figures 1–6.
Study limitations
- Molecular detection does not prove identical pharmacology or clinical equivalence.
- The paper’s discussion of clinical work is not an independent clinical trial.
Reviewed 2026-11-15.
Related compound research
Follow shared publications or research classes. These links do not establish equivalent effects between compounds.
Research collection curated by @PepMariner · editorial standards. Send a source correction ↗
Browse bibliography & PDFs ↗